Priya Rastogi

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
  2. ncbi Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal gr
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
    J Clin Oncol 30:3792-9. 2012
  3. ncbi Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    Priya Rastogi
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 11:228-34. 2011
  4. ncbi Chemoprevention in postmenopausal women
    Priya Rastogi
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Menopause 15:810-5. 2008
  5. ncbi Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Washington Cancer Institute at Washington Hospital Center, Washington, DC 20010, USA
    N Engl J Med 362:2053-65. 2010
  6. ncbi What do perceived cognitive problems reflect?
    Catherine M Bender
    University of Pittsburgh School of Nursing, 3500 Victoria Street, Suite 415, Pittsburgh, PA 15261, USA
    J Support Oncol 6:238-42. 2008
  7. ncbi Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project (NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
  8. ncbi Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Pittsburgh, PA 15261, USA
    Menopause 14:995-8. 2007
  9. ncbi Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    John T Hamm
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Philadelphia, PA, USA
    Clin Breast Cancer 8:257-63. 2008
  10. ncbi Update on breast cancer prevention
    Priya Rastogi
    Breast Cancer Prevention Program, Magee Women s Hospital University of Pittsburgh, Department of Medicine, Section of Hematology Oncology, School of Medicine, Pittsburgh, Pennsylvania, USA
    Oncology (Williston Park) 17:799-805; discussion 808-10, 813. 2003

Collaborators

Detail Information

Publications10

  1. ncbi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS...
  2. ncbi Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal gr
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
    J Clin Oncol 30:3792-9. 2012
    ..Given the demonstrated efficacy of trastuzumab, ongoing assessment of cardiac safety and identification of risk factors for CD are important for optimal patient care...
  3. ncbi Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    Priya Rastogi
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 11:228-34. 2011
    ..The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC)...
  4. ncbi Chemoprevention in postmenopausal women
    Priya Rastogi
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Menopause 15:810-5. 2008
    ..Raloxifene offers an acceptable option for breast cancer risk reduction in postmenopausal women...
  5. ncbi Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Washington Cancer Institute at Washington Hospital Center, Washington, DC 20010, USA
    N Engl J Med 362:2053-65. 2010
    ..The effectiveness of concurrent versus sequential regimens is not known...
  6. ncbi What do perceived cognitive problems reflect?
    Catherine M Bender
    University of Pittsburgh School of Nursing, 3500 Victoria Street, Suite 415, Pittsburgh, PA 15261, USA
    J Support Oncol 6:238-42. 2008
    ..At a minimum, our results indicated that women's complaints of cognitive problems should prompt additional assessment to clarify the bases of the problem and initiate appropriate intervention...
  7. ncbi Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project (NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..CONCLUSION: Administering trastuzumab with paclitaxel after AC increases incidence of CHF and lesser CD. Potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy...
  8. ncbi Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Pittsburgh, PA 15261, USA
    Menopause 14:995-8. 2007
    ..We hypothesized, therefore, that anastrozole would have a more profound effect on cognitive function than tamoxifen, a mixed estrogen agonist/antagonist...
  9. ncbi Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    John T Hamm
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Philadelphia, PA, USA
    Clin Breast Cancer 8:257-63. 2008
    ..This trial also evaluated the feasibility of tissue collection for gene-expression profiling...
  10. ncbi Update on breast cancer prevention
    Priya Rastogi
    Breast Cancer Prevention Program, Magee Women s Hospital University of Pittsburgh, Department of Medicine, Section of Hematology Oncology, School of Medicine, Pittsburgh, Pennsylvania, USA
    Oncology (Williston Park) 17:799-805; discussion 808-10, 813. 2003
    ..The Study of Tamoxifen and Raloxifene is designed to compare the efficacy of tamoxifen and raloxifene in reducing breast cancer risk. Aromatase inhibitors will also be studied in the setting of chemoprevention for breast cancer...